View:
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 22, 2005
PRO-PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Nevada 000-32877 04-3562325
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
189 Wells Avenue, Newton, Massachusetts 02459
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 559-0033
________________________________________________________________________________
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On March 22, 2005, we issued a news release announcing results of experiments
that reveal when DAVANAT(R) is co-administrated with 5-FU and the anti-Vascular
Endothelial Growth Factor (VEGF) drug, Avastin(TM), to mice implanted with human
colon tumor (COLO 205), DAVANAT(R) significantly improves anti-tumor activities
of the combination and doubles the tumor shrinkage rate. The news release is
furnished as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
99.1 News release of Pro-Pharmaceuticals, Inc. dated March 22, 2005.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PRO-PHARMACEUTICALS, INC.
By: /s/ David Platt
-------------------------------------
David Platt
President and Chief Executive Officer
Date: March 23, 2005
Exhibit 99.1
Pro-Pharmaceuticals' Lead Compound DAVANAT Enhances Anti-Tumor
Activity of Avastin/5-FU in Pre-Clinical Studies; Data Presented at
Glycomics & Carbohydrates Conference
NEWTON, Mass.--(BUSINESS WIRE)--March 22,
2005--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel
carbohydrate compounds that enable the targeted delivery of
chemotherapy drugs to cancer cells, today announced encouraging
results of pre-clinical experiments that include Avastin(TM),
5-Fluorouracil (5-FU) and DAVANAT(R). The data is being presented at
the 3rd Annual Glycomics and Carbohydrates in Drug Development
Conference held at the Hilton Hotel in La Jolla, California by Eliezer
Zomer, Ph.D., Vice President, Product Development & Manufacturing,
Pro-Pharmaceuticals.
The presentation highlights results of experiments that reveal
when DAVANAT(R) is co-administrated with 5-FU and the anti-Vascular
Endothelial Growth Factor (VEGF) drug, Avastin(TM) to mice implanted
with human colon tumor (COLO 205), DAVANAT(R) significantly improves
anti-tumor activities of the combination and doubles the tumor
shrinkage rate. Avastin(TM) was approved in February 2004 as a
first-line treatment for metastatic colorectal cancer in combination
with intravenous 5-FU-based chemotherapy.
"We saw significant improved anti-tumor activity when
co-administering DAVANAT(R) with Avastin(TM)/5-FU as compared with
Avastin(TM)/5-FU," said Anatole Klyosov, Ph.D., D.Sc., Consulting
Chief Scientist, Pro-Pharmaceuticals. "These results are encouraging
and warrant further investigation."
About DAVANAT(R)
DAVANAT(R) is a proprietary polysaccharide in a CARBOSOME(TM
)formulation that enables the targeted delivery of chemotherapy drugs
to protein receptors (lectins) that are unique to cancer cells.
Pro-Pharmaceuticals, Inc. - Advancing Drugs Through
Glycoscience(R)
Pro-Pharmaceuticals is a drug development company commercializing
a new generation of anti-cancer treatments using carbohydrate
compounds to Glyco-Upgrade(TM) the safety and efficacy of FDA-approved
chemotherapy drugs. The Company has been conducting pre-clinical
studies for irinotecan, doxorubicin, oxaliplatin, paclitaxel,
cyclophosphamide, cisplatin, and most recently with bevacizumab
co-administrated with DAVANAT(R) and other polysaccharide compounds.
Human colon and breast xenography are being used to optimize regimens
and results show that DAVANAT(R) exhibits a broad spectrum of
enhancement with tested drugs. Additional information is available at
www.pro-pharmaceuticals.com.
FORWARD LOOKING STATEMENTS: Any statements in this news release
about future expectations, plans and prospects for the Company,
including without limitation statements containing the words
"believes," "anticipates," "plans," "expects," and similar
expressions, constitute forward-looking statements as defined in the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Because of uncertainties and risks facing the Company,
many of which are outside of the Company's control, future events
could cause actual results to differ materially from those indicated
by such statements. More information about those risks and
uncertainties is contained and discussed in the "Management Discussion
and Analysis of Financial Condition and Results of Operations" and
"Risk Factors" sections of the Company's most recent quarterly or
annual report and in the Company's other reports filed with the
Securities and Exchange Commission. The forward-looking statements
herein represent the Company's views as of the date of this press
release and should not be relied upon to represent the Company's views
as of a subsequent date. While the Company anticipates that subsequent
events may cause the Company's views to change, the Company disclaims
any obligation to update such forward-looking statements.
Contact: Pro-Pharmaceuticals, Inc., Anthony D. Squeglia:
617.559.0033; squeglia@pro-pharmaceuticals.com.
DAVANAT and Advancing Drugs Through Glycoscience are registered
trademarks of Pro-Pharmaceuticals. Glyco-Upgrade is a trademark of
Pro-Pharmaceuticals. CARBOSOME is a trademark of Pro-Pharmaceuticals.
Avastin is a trademark of Genentech, Inc.
CONTACT: Pro-Pharmaceuticals, Inc.
Anthony D. Squeglia, 617-559-0033
squeglia@pro-pharmaceuticals.com